Imugene Limited has announced the successful completion of the initial phase of its OASIS clinical trial.

Eilean Therapeutics LLC announced that its Australian subsidiary has received approval from the Human Research Ethics Committee to begin a Phase 1 clinical trial of balamenib (ZE63-0302).

Regulus Therapeutics has reported promising outcomes from the second group of participants in a Phase 1b clinical trial for a new drug, RGLS8429.

The trial is assessing the efficacy of KVA12123, a VISTA-blocking immunotherapy, both as a standalone treatment and in conjunction with Merck’s KEYTRUDA® (pembrolizumab).

Roche has recently announced at an online investor event that their experimental drug for Alzheimer's disease, trontinemab.

The trial will evaluate the safety, tolerability, and pharmacokinetics of CMND-100, an oral capsule derived from MEAI, for patients with alcohol use disorder (AUD).

Lineage Cell Therapeutics, has announced the upcoming presentation of two-year outcomes from a Phase 1/2a study of RG6501, also known as OpRegen.

In Durham, N.C., Atsena Therapeutics announced that the second group in their LIGHTHOUSE study has started receiving doses of ATSN-201.

Biotechnology firm Ocugen, Inc. has announced the completion of dosing for the initial group in its Phase 1/2 clinical trial for OCU410.

AI-driven drug discovery firm Expert Systems has reached a key milestone with its partner, Eilean Therapeutics, by initiating the first phase of clinical trials for balamenib (ZE63-0302).

Faron Pharmaceuticals, a biopharmaceutical firm specializing in innovative immunotherapies, has announced the scheduling of a virtual BEXMAB study update session.

The clinical trial will explore Gynica's proprietary cannabinoid-based formulations, which are administered intravaginally, leveraging the therapeutic potential of cannabinoids in women's health.